Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics.
hexima.com.au
Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting a 132 patient Australian phase IIb clinical trial of HXP124 for onychomycosis. Hexima holds granted, long-life patents protecting HXP124 in major markets globally.
Hexima is based in Melbourne, Australia.
It is anticipated that HXL will list on the ASX during December 2020.
Hexima Home – Hexima
Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.
hexima.com.au
Be the first to comment